AssetMark Inc
PRAX icon

AssetMark Inc’s Praxis Precision Medicines PRAX Stock Holding History

AssetMark Inc’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335 Buy
+1
New +$317 ﹤0.01% 3359
2025
Q1 		– Sell
-7
Closed -$539 – 2736
2024
Q4 		$539 Buy
+7
New +$506 ﹤0.01% 2360

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

AssetMark Inc's PRAX Position: Q2 2026 in Review

AssetMark Inc opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 1 share worth $335. The stake represents ﹤0.01% of the portfolio and ranks #3359 among its holdings. This is a return to the name: AssetMark Inc previously reported a position in PRAX as recently as Q4 2024.

AssetMark Inc first reported a position in PRAX in Q4 2024 and has held it in 2 quarters since. The position peaked at $539 in Q4 2024. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • AssetMark Inc held 1 share of Praxis Precision Medicines worth $335 as of Q2 2026.
  • Praxis Precision Medicines was a new AssetMark Inc position in Q2 2026.
  • Praxis Precision Medicines made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3359 holding.
  • AssetMark Inc first reported a position in Praxis Precision Medicines in Q4 2024 and has held it in 2 quarters since.
  • AssetMark Inc's Praxis Precision Medicines position peaked at $539 in Q4 2024.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.